CoChat

Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay

Open access
Clifton, Katherine, Rich, Thereasa A., Parseghian, Christine, Raymond, Victoria M., Dasari, Arvind, Pereira, Allan Andresson Lima, Willis, Jason, Loree, Jonathan M., Bauer, Todd M., Chae, Young Kwang, Sherrill, Gary, Fanta, Paul, Grothey, Axel, Hendifar, Andrew, Henry, David, Mahadevan, Daruka, Nezami, Mohammad Amin, Tan, Benjamin, Wainberg, Zev A., Lanman, Richard, Kopetz, Scott, Morris, Van · 2019 · JCO Precision Oncology
Cited by 37

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

PURPOSE: Gene fusions are established oncogenic drivers and emerging therapeutic targets in advanced colorectal cancer. This study aimed to detail the frequencies and clinicopathological features of gene fusions in colorectal cancer using a circulating tumor DNA assay. METHODS: Circulating tumor DNA samples in patients with advanced colorectal cancer were analyzed at 4,581 unique time points using a validated plasma-based multigene assay that includes assessment of fusions in FGFR2, FGFR3, RET, ALK, NTRK1, and ROS1. Associations between fusions and clinicopathological features were measured using Fisher’s exact test. Relative frequencies of genomic alterations were compared between fusion-present and fusion-absent cases using an unpaired t test. RESULTS: Forty-four unique fusions were identified in 40 (1.1%) of the 3,808 patients with circulating tumor DNA detected: RET (n = 6; 36% of all fusions detected), FGFR3 (n = 2; 27%), ALK (n = 10, 23%), NTRK1 (n = 3; 7%), ROS1 (n = 2; 5%), and FGFR2 (n = 1; 2%). Relative to nonfusion variants detected, fusions were more likely to be subclonal (odds ratio, 8.2; 95% CI, 2.94 to 23.00; P < .001). Mutations associated with a previously reported anti–epidermal growth factor receptor (anti-EGFR) therapy resistance signature (subclonal RAS and EGFR mutations) were found with fusions in FGFR3 (10 of 12 patients), RET (nine of 16 patients), and ALK (seven of 10 patients). For the 27 patients with available clinical histories, 21 (78%) had EGFR monoclonal antibody treatment before fusion detection. CONCLUSION: Diverse and potentially actionable fusions can be detected using a circulating tumor DNA assay in patients with advanced colorectal cancer. Distribution of coexisting subclonal mutations in EGFR, KRAS, and NRAS in a subset of the patients with fusion-present colorectal cancer suggests that these fusions may arise as a novel mechanism of resistance to anti-EGFR therapies in patients with metastatic colorectal cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/po.19.00141

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 37

Metadata

Authors
Clifton, K., Rich, T. A., Parseghian, C., Raymond, V. M., Dasari, A., Pereira, A. A. L., Willis, J., Loree, J. M., Bauer, T. M., Chae, Y. K., Sherrill, G., Fanta, P., Grothey, A., Hendifar, A., Henry, D., Mahadevan, D., Nezami, M. A., Tan, B., Wainberg, Z. A., Lanman, R., Kopetz, S., & Morris, V.
Venue
JCO Precision Oncology
Published
2019-12
Volume
3
Issue
3
Pages
1-15
ISSN
2473-4284 (ISSN-L)
OpenAlex
W2977377261
Cited by
37
References
9
FWCI
1.90
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. https://app.cochat.ai/papers/10.1200/po.19.00141
The paper
Clifton, K., Rich, T. A., Parseghian, C., Raymond, V. M., Dasari, A., Pereira, A. A. L., Willis, J., Loree, J. M., Bauer, T. M., Chae, Y. K., Sherrill, G., Fanta, P., Grothey, A., Hendifar, A., Henry, D., Mahadevan, D., Nezami, M. A., Tan, B., Wainberg, Z. A., . . . Morris, V. (2019). Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. JCO Precision Oncology. https://doi.org/10.1200/po.19.00141

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.